Toggle Main Menu Toggle Search

Open Access padlockePrints

APOE genotype makes a small contribution to warfarin dose requirements

Lookup NU author(s): Elizabeth Sconce, Professor Ann DalyORCiD, Dr Tayyaba Khan, Dr Hilary Wynne, Professor Farhad Kamali


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Alterations in vitamin K availability can significantly influence anticoagulation response to warfarin. Apolipoprotein E (APOE) plays a part in the hepatic uptake of lipid-soluble vitamin K. This study aimed to determine the influence of common polymorphisms in the APOE gene on warfarin dose requirements. patients with stable anticoagulation control and with a target International Normalized Ratio (INR) 2.0-3.0 were genotyped for the APOE ε2, ε3 and ε4 variants. Mean±SD daily warfarin doses were significantly lower in patients carrying at least one ε4 allele compared to the ε3ε3 reference genotype (3.3±1.9 versus 4.0±1.8; P=0.03; 95% CI: 0.1-1.2). Multivariate regression analysis showed that patient age, height and CYP2C9, VKORC1 and APOE genotypes significantly contributed to warfarin dose requirement (R=57%). only the ε4 allele of APOE was found to make a significant (P=0.002) but small contribution to warfarin dose requirement. There was no significant difference in fasted plasma vitamin K concentration between patients with the different APOE genotypes. This study suggests that APOE genotype is unlikely to have a clinically significant effect on warfarin dose requirements. © 2006 Lippincott Williams & Wilkins.

Publication metadata

Author(s): Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F

Publication type: Article

Publication status: Published

Journal: Pharmacogenetics and Genomics

Year: 2006

Volume: 16

Issue: 8

Pages: 609-611

ISSN (print): 1744-6872

ISSN (electronic): 1744-6880

Publisher: Lippincott Williams & Wilkins


DOI: 10.1097/01.fpc.0000220567.98089.b5

PubMed id: 16847429


Altmetrics provided by Altmetric